Section of Adult Neurology, Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines- Manila, Manila, Philippines.
J Clin Neurosci. 2020 Apr;74:41-46. doi: 10.1016/j.jocn.2020.01.057. Epub 2020 Jan 23.
Cost of illness (COI) studies are used to estimate the economic burden of a particular disease. The chronicity of Parkinson's disease (PD) and its lack of treatment make its projected economic burden to grow substantially over the next few decades.
To evaluate the cost of having PD, a COI study was done in a public tertiary hospital in Metro Manila, Philippines. PD patients who were consecutively seen at out patient clinic for a period of six months were included in this study and were interviewed using a ready-made financial burden questionnaire. To identify the possible factors that may affect the cost, European Quality of Life 5 Dimensions (EQ5D), Montreal Cognitive Assessment-Philippines (MoCA-P), Hospital Anxiety and Depression Scale-Pilipino (HADS-P), Unified Parkinson's Disease Rating Scale (UPDRS) motor and activities of daily living (ADL) scores, Schwab and England ADL and Hoehn and Yahr scoring were also administered.
Thirty three consecutive PD patients (mean age: 58.4 yrs, men: 52%) were identified. The annual total cost of PD per capita was Php 308,796 (USD 6175) with direct cost accounting for 23% and indirect cost 77%. The main cost components for direct medical, direct non-medical and indirect cost were pharmacotherapy (97%), home care (42.6%) and productivity loss (100%) respectively. The factors observed to have high cost of PD included being male, married, employed, the presence of wearing off phenomenon, low MOCA-P and HADS-P, low Schwab and England ADL and increasing Hoehn and Yahr stage.
This study showed that PD is a costly neurodegenerative disease that may pose a significant economic burden on patients, health care system and society.
疾病经济负担（COI）研究用于评估特定疾病的经济负担。帕金森病（PD）的慢性特征及其缺乏有效治疗方法使得其未来几十年的经济负担预计会大幅增加。
为了评估 PD 的成本，在菲律宾马尼拉大都会的一家公立医院进行了一项 COI 研究。连续六个月在门诊就诊的 PD 患者被纳入本研究，并使用现成的经济负担问卷进行访谈。为了确定可能影响成本的因素，还进行了欧洲生活质量 5 维度（EQ5D）、菲律宾蒙特利尔认知评估（MoCA-P）、菲律宾医院焦虑和抑郁量表（HADS-P）、统一帕金森病评定量表（UPDRS）运动和日常生活活动（ADL）评分、Schwab 和 England ADL 以及 Hoehn 和 Yahr 评分。
共确定了 33 例连续 PD 患者（平均年龄：58.4 岁，男性：52%）。人均 PD 年总费用为 308796 菲律宾比索（6175 美元），直接成本占 23%，间接成本占 77%。直接医疗、直接非医疗和间接成本的主要成本构成部分分别为药物治疗（97%）、家庭护理（42.6%）和生产力损失（100%）。观察到导致 PD 高成本的因素包括男性、已婚、有工作、存在药效减退现象、MoCA-P 和 HADS-P 较低、Schwab 和 England ADL 较低以及 Hoehn 和 Yahr 分期增加。
本研究表明，PD 是一种昂贵的神经退行性疾病，可能给患者、医疗保健系统和社会带来重大经济负担。
